Management of Psychotropic Medication Side Effects in Children and Adolescents

Child and Adolescent Psychiatric Clinics of North America

Volumn 21, Issue 4, 2012, Pages 713-738

  Garcia, Georgina ^a,b   Logan, Grace E ^a   Gonzalez Heydrich, Joseph ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antidepressants; Antipsychotics; Citalopram; Mood Stabilizers; SSRI; Stimulants; Suicide; Treatment of side effects

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATOMOXETINE; BUSPIRONE; CITALOPRAM; CLONIDINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FLUVOXAMINE MALEATE; GUANFACINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; PLACEBO; PREXEVA; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VILAZODONE;

ABDOMINAL DISCOMFORT; ACNE; ADJUVANT THERAPY; ADVERSE OUTCOME; AGITATION; AKATHISIA; ANOREXIA; ANTICHOLINERGIC SYNDROME; ANXIETY; ANXIETY DISORDER; ASEPTIC MENINGITIS; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BLEEDING; BLOOD DYSCRASIA; BLURRED VISION; BONE MARROW SUPPRESSION; BRADYCARDIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHILD HEALTH CARE; CLINICAL EFFECTIVENESS; COGNITION; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CONTACT DERMATITIS; DELIRIUM; DEPRESSION; DERMATITIS; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRESS SYNDROME; DROWSINESS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EDEMA; ELECTROCARDIOGRAM; EVIDENCE BASED MEDICINE; EXCITEMENT; EXTRAPYRAMIDAL SYMPTOM; EYE DISEASE; FAINTNESS; FATIGUE; FETUS MALFORMATION; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; GROWTH RATE; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPARATHYROIDISM; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPONATREMIA; HYPOTENSION; HYPOTHYROIDISM; INSOMNIA; IRRITABILITY; LEUKOPENIA; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; MANIA; MENSTRUATION DISORDER; MENTAL DISEASE; METABOLIC ACIDOSIS; METABOLIC SYNDROME X; MIGRAINE; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPHIL COUNT; ORTHOSTATIC HYPOTENSION; OSTEOPENIA; OSTEOPOROSIS; PARESTHESIA; PARKINSONISM; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PIGMENT DISORDER; PRIAPISM; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; QT INTERVAL; QT PROLONGATION; RESTLESSNESS; RETINA PIGMENT DEGENERATION; REVIEW; SEDATION; SEIZURE; SEIZURE THRESHOLD; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SOCIAL ISOLATION; STEVENS JOHNSON SYNDROME; SUICIDE; SWEATING; TACHYCARDIA; TARDIVE DYSKINESIA; THROMBOCYTE COUNT; TIC; TREATMENT PLANNING; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADOLESCENT; CHILD; HUMANS; METABOLIC SYNDROME X; MOVEMENT DISORDERS; PSYCHOTROPIC DRUGS; RISK ASSESSMENT; SUICIDAL IDEATION;

EID: 84867079339     PISSN: 10564993     EISSN: 15580490     Source Type: Journal    
DOI: 10.1016/j.chc.2012.07.012     Document Type: Review

References (136)

1. Goethe J.W., Woolley S.B., Cardoni A.A., et al. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J Clin Psychopharmacol 2007, 27(5):451-458.
2. Safer D.J., Zito J.M. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol 2006, 16(1-2):159-169.
3. FDA. 2012. Available at: Accessed March 28, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.
4. Boeck V., Overo K.F., Svendsen O. Studies on acute toxicity and drug levels of citalopram in the dog. Acta Pharmacol Toxicol (Copenh) 1982, 50(3):169-174.
5. Tarabar A.F., Hoffman R.S., Nelson L. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol 2008, 4(2):101-105.
6. McNally P., McNicholas F., Oslizlok P. The QT interval and psychotropic medications in children: recommendations for clinicians. Eur Child Adolesc Psychiatry 2007, 16(1):33-47.
7. Gibbons R.D., Mann J.J. Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned?. Drug Saf 2011, 34(5):375-395.
8. FDA. Public Health Advisory: Antidepressant Use in Children, Adolescents, and Adults. 2004. Available at: Accessed February 27, 2012. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm155489.htm.
9. FDA. Antidepressant Use in Children, Adolescents, and Adults. 2006. Available at: Accessed February 27, 2012. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/UCM096273.
10. Hammad T.A., Laughren T., Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006, 63(3):332-339.
11. Carpenter D.J., Fong R., Kraus J.E., et al. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. J Clin Psychiatry 2011, 72(11):1503-1514.
12. Olfson M., Marcus S.C., Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch Gen Psychiatry 2006, 63(8):865-872.
13. Gibbons R.D., Brown C.H., Hur K., et al. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012, 69(6):580-587.
14. Leon A.C., Solomon D.A., Li C., et al. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry 2011, 72(5):580-586.
15. Carlson G.A., Mick E. Drug-induced disinhibition in psychiatrically hospitalized children. J Child Adolesc Psychopharmacol 2003, 13(2):153-163.
16. Goodman W.K., Murphy T.K., Storch E.A. Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology (Berl) 2007, 191(1):87-96.
17. Walkup J., Labellarte M. Complications of SSRI treatment. J Child Adolesc Psychopharmacol 2001, 11(1):1-4.
18. Faedda G.L., Baldessarini R.J., Glovinsky I.P., et al. Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review. J Affect Disord 2004, 82(1):149-158.
19. Henry C., Sorbara F., Lacoste J., et al. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry 2001, 62(4):249-255.
20. Truman C.J., Goldberg J.F., Ghaemi S.N., et al. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 2007, 68(10):1472-1479.
21. Kowatch R.A., Youngstrom E.A., Danielyan A., et al. Review and meta-analysis of the phenomenology and clinical characteristics of mania in children and adolescents. Bipolar Disord 2005, 7(6):483-496.
22. Bridge J.A., Iyengar S., Salary C.B., et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007, 297(15):1683-1696.
23. Brent D.A., Greenhill L.L., Compton S., et al. The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry 2009, 48(10):987-996.
24. Jones L. Responding to the needs of children in crisis. Int Rev Psychiatry 2008, 20(3):291-303.
25. Parker G., Brotchie H. Gender differences in depression. Int Rev Psychiatry 2010, 22(5):429-436.
26. Restifo K., Bogels S. Family processes in the development of youth depression: translating the evidence to treatment. Clin Psychol Rev 2009, 29(4):294-316.
27. Thapar A., Collishaw S., Pine D.S., et al. Depression in adolescence. Lancet 2012, 379(9820):1056-1067.
28. Goodyer I., Dubicka B., Wilkinson P., et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007, 335(7611):142.
29. March J., Silva S., Petrycki S., et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004, 292(7):807-820.
30. Stanley B., Brown G., Brent D.A., et al. Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. J Am Acad Child Adolesc Psychiatry 2009, 48(10):1005-1013.
31. Vitiello B., Brent D.A., Greenhill L.L., et al. Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. J Am Acad Child Adolesc Psychiatry 2009, 48(10):997-1004.
32. Wilens T.E., Biederman J., Kwon A., et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 2003, 13(2):143-152.
33. Anderson H.D., Pace W.D., Libby A.M., et al. Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study. Clin Ther 2012, 34(1):113-123.
34. Smitherman T.A., Walters A.B., Maizels M., et al. The use of antidepressants for headache prophylaxis. CNS Neurosci Ther 2011, 17(5):462-469.
35. Punay N.C., Couch J.R. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 2003, 7(1):51-54.
36. Moja P.L., Cusi C., Sterzi R.R., et al. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005, (3). CD002919.
37. Murphy T.K., Segarra A., Storch E.A., et al. SSRI adverse events: how to monitor and manage. Int Rev Psychiatry 2008, 20(2):203-208.
38. Norgaard M., Jacobsen J., Gasse C., et al. Selective serotonin reuptake inhibitors and risk of acute pancreatitis: a population-based case-control study. J Clin Psychopharmacol 2007, 27(3):259-262.
39. Spigset O., Hagg S., Bate A. Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int Clin Psychopharmacol 2003, 18(3):157-161.
40. Birmaher B., Brent D., Bernet W., et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007, 46(11):1503-1526.
41. Dodd S., Malhi G.S., Tiller J., et al. A consensus statement for safety monitoring guidelines of treatments for major depressive disorder. Aust N Z J Psychiatry 2011, 45(9):712-725.
42. Harvey B.H., Bouwer C.D. Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clin Neuropharmacol 2000, 23(2):90-97.
43. Sussman N. Venlafaxine XR therapy for major depression and anxiety disorders. The clinical implications that its advantages pose. Postgrad Med 1999, 106(Suppl 6):31-36.
44. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000, 61(Suppl 11):37-41.
45. Croft H., Houser T.L., Jamerson B.D., et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther 2002, 24(4):662-672.
46. Harto-Truax N., Stern W.C., Miller L.L., et al. Effects of bupropion on body weight. J Clin Psychiatry 1983, 44(5 Pt 2):183-186.
47. Weisler R.H., Johnston J.A., Lineberry C.G., et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994, 14(3):170-179.
48. Goodnick P.J., Goldstein B.J. Selective serotonin reuptake inhibitors in affective disorders-I. Basic pharmacology. J Psychopharmacol 1998, 12(3 Suppl B):S5-S20.
49. Montgomery S.A. Efficacy and safety of the selective serotonin reuptake inhibitors in treating depression in elderly patients. Int Clin Psychopharmacol 1998, 13(Suppl 5):S49-S54.
50. Smith W.T., Glaudin V., Panagides J., et al. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990, 26(2):191-196.
51. Herva A., Laitinen J., Miettunen J., et al. Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study. Int J Obes (Lond) 2006, 30(3):520-527.
52. Patten S.B., Williams J.V., Lavorato D.H., et al. Major depression, antidepressant medication and the risk of obesity. Psychother Psychosom 2009, 78(3):182-186.
53. Patten S.B., Williams J.V., Lavorato D.H., et al. Weight gain in relation to major depression and antidepressant medication use. J Affect Disord 2011, 134(1-3):288-293.
54. Comer J.S., Olfson M., Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry 2010, 49(10):1001-1010.
55. Findling R.L., Drury S.S., Jensen P.S. Practice parameter for the use of atypical antipsychotic medications in children. J Am Acad Child Adolesc Psychiatry 2011, Accessed August 23, 2012. http://www.aacap.org/galleries/PracticeParameters/Atypical_Antipsychotic_Medications_Web.pdf.
56. Mojtabai R., Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010, 67(1):26-36.
57. Naber D., Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009, 23(8):649-659.
58. Rani F.A., Byrne P.J., Murray M.L., et al. Paediatric atypical antipsychotic monitoring safety (PAMS) study: pilot study in children and adolescents in secondary- and tertiary-care settings. Drug Saf 2009, 32(4):325-333.
59. Laita P., Cifuentes A., Doll A., et al. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 2007, 17(4):487-502.
60. Caroff S.N., Hurford I., Lybrand J., et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin 2011, 29(1):127-148. viii.
61. Correll C.U., Leucht S., Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004, 161(3):414-425.
62. Miller D.D., Caroff S.N., Davis S.M., et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008, 193(4):279-288.
63. Correll C.U. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008, 69(Suppl 4):26-36.
64. Simpson G.M. The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry 2000, 61(Suppl 4):39-44.
65. Soares K.V., McGrath J.J. The treatment of tardive dyskinesia-a systematic review and meta-analysis. Schizophr Res 1999, 39(1):1-16. [discussion 17-8].
66. van Harten P.N., Tenback D.E. Tardive dyskinesia: clinical presentation and treatment. Int Rev Neurobiol 2011, 98:187-210.
67. Cook S., Auinger P., Li C., et al. Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999-2002. J Pediatr 2008, 152(2):165-170.
68. D'Adamo E., Santoro N., Caprio S. Metabolic syndrome in pediatrics: old concepts revised, new concepts discussed. Pediatr Clin North Am 2011, 58(5):1241-1255. xi.
69. Maayan L., Correll C.U. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2011, 21(6):517-535.
70. Steinberger J., Daniels S.R., Eckel R.H., et al. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2009, 119(4):628-647.
71. Jerrell J.M., McIntyre R.S. Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol 2008, 23(4):283-290.
72. Correll C.U., Manu P., Olshanskiy V., et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302(16):1765-1773.
73. De Hert M., Vancampfort D., Correll C.U., et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry 2011, 199(2):99-105.
74. Panagiotopoulos C., Ronsley R., Kuzeljevic B., et al. Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with second-generation antipsychotics. Can J Psychiatry 2012, 57(1):34-44.
75. Pringsheim T., Panagiotopoulos C., Davidson J., et al. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry 2011, 20(3):218-233.
76. Seida J.C., Schouten J.R., Boylan K., et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 2012, 129(3):e771-e784.
77. Battista M., Murray R.D., Daniels S.R. Use of the metabolic syndrome in pediatrics: a blessing and a curse. Semin Pediatr Surg 2009, 18(3):136-143.
78. Ho J., Panagiotopoulos C., McCrindle B., et al. Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. J Can Acad Child Adolesc Psychiatry 2011, 20(3):234-241.
79. Vitiello B., Correll C., van Zwieten-Boot B., et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 2009, 19(9):629-635.
80. De Hert M., Dobbelaere M., Sheridan E.M., et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011, 26(3):144-158.
81. Rummel-Kluge C., Komossa K., Schwarz S., et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010, 123(2-3):225-233.
82. Stigler K.A., Potenza M.N., McDougle C.J. Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs 2001, 3(12):927-942.
83. FDA. Suicidal Behavior and Ideation and Antiepileptic Drugs. 2008. Available at: Accessed February 27, 2012. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100190.htm.
84. Dennehy E.B., Marangell L.B., Allen M.H., et al. Suicide and suicide attempts in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Affect Disord 2011, 133(3):423-427.
85. Harris K.M., McLean J.P., Sheffield J., et al. The internal suicide debate hypothesis: exploring the life versus death struggle. Suicide Life Threat Behav 2010, 40(2):181-192.
86. Rihmer Z., Gonda X. The effect of pharmacotherapy on suicide rates in bipolar patients. CNS Neurosci Ther 2012, 18(3):238-242.
87. Kalinin V.V. Suicidality and antiepileptic drugs: is there a link?. Drug Saf 2007, 30(2):123-142.
88. Andersohn F., Schade R., Willich S.N., et al. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 2010, 75(4):335-340.
89. Arana A., Wentworth C.E., Ayuso-Mateos J.L., et al. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010, 363(6):542-551.
90. Leon A.C., Solomon D.A., Li C., et al. antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study. Am J Psychiatry 2012, 169(3):285-291.
91. Bessmertny O., Pham T. Antiepileptic hypersensitivity syndrome: clinicians beware and be aware. Curr Allergy Asthma Rep 2002, 2(1):34-39.
92. Knowles S.R., Shapiro L.E., Shear N.H. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999, 21(6):489-501.
93. Kumari R., Timshina D.K., Thappa D.M. Drug hypersensitivity syndrome. Indian J Dermatol Venereol Leprol 2011, 77(1):7-15.
94. Hebert A.A., Ralston J.P. Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry 2001, 62(Suppl 14):22-26.
95. Mansur A.T., Pekcan Yasar S., Goktay F. Anticonvulsant hypersensitivity syndrome: clinical and laboratory features. Int J Dermatol 2008, 47(11):1184-1189.
96. Aiken C.B., Orr C. Rechallenge with lamotrigine after a rash: a prospective case series and review of the literature. Psychiatry (Edgmont) 2010, 7(5):27-32.
97. Lekhwani M., Nair C., Nikhinson I., et al. Psychotropic prescription practices in child psychiatric inpatients 9 years old and younger. J Child Adolesc Psychopharmacol 2004, 14(1):95-103.
98. Najjar F., Welch C., Grapentine W.L., et al. Trends in psychotropic drug use in a child psychiatric hospital from 1991-1998. J Child Adolesc Psychopharmacol 2004, 14(1):87-93.
99. Elbe D., Savage R. How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications. J Can Acad Child Adolesc Psychiatry 2010, 19(1):40-45.
100. McKnight R.F., Adida M., Budge K., et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012, 379(9817):721-728.
101. Gerrett D., Lamont T., Paton C., et al. Prescribing and monitoring lithium therapy: summary of a safety report from the National Patient Safety Agency. BMJ 2010, 341:c6258.
102. Nicholson J., Fitzmaurice B. Monitoring patients on lithium-a good practice guideline. Psychiatrist 2002, 26:348-351.
103. Hammerness P.G., Perrin J.M., Shelley-Abrahamson R., et al. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry 2011, 50(10):978-990.
104. Ivanenko A., Johnson K. Sleep disturbances in children with psychiatric disorders. Semin Pediatr Neurol 2008, 15(2):70-78.
105. Corkum P., Tannock R., Moldofsky H. Sleep disturbances in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1998, 37(6):637-646.
106. Day H.D., Abmayr S.B. Parent reports of sleep disturbances in stimulant-medicated children with attention-deficit hyperactivity disorder. J Clin Psychol 1998, 54(5):701-716.
107. Ring A., Stein D., Barak Y., et al. Sleep disturbances in children with attention-deficit/hyperactivity disorder: a comparative study with healthy siblings. J Learn Disabil 1998, 31(6):572-578.
108. Sonuga-Barke E.J., Coghill D., Wigal T., et al. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol 2009, 19(6):683-690.
109. Corkum P., Panton R., Ironside S., et al. Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder. J Pediatr Psychol 2008, 33(4):368-379.
110. Kent J.D., Blader J.C., Koplewicz H.S., et al. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. Pediatrics 1995, 96(2 Pt 1):320-325.
111. Stein M.A., Blondis T.A., Schnitzler E.R., et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics 1996, 98(4 Pt 1):748-756.
112. Faraone S.V., Glatt S.J., Bukstein O.G., et al. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord 2009, 12(4):308-315.
113. Kim H.W., Yoon I.Y., Cho S.C., et al. The effect of OROS methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder. Int Clin Psychopharmacol 2010, 25(2):107-115.
114. Sangal R.B., Owens J., Allen A.J., et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 2006, 29(12):1573-1585.
115. Weiss M.D., Wasdell M.B., Bomben M.M., et al. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J Am Acad Child Adolesc Psychiatry 2006, 45(5):512-519.
116. FDA. Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder-Communication about an Ongoing Safety Review. 2009. Available at: Accessed February 27, 2012. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm166667.htm.
117. Findling R.L., Biederman J., Wilens T.E., et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr 2005, 147(3):348-354.
118. Rapport M.D., Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 2002, 22(8):1107-1131.
119. Samuels J.A., Franco K., Wan F., et al. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006, 21(1):92-95.
120. Vitiello B., Elliott G.R., Swanson J.M., et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry 2012, 169(2):167-177.
121. Schelleman H., Bilker W.B., Kimmel S.E., et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry 2012, 169(2):178-185.
122. Habel L.A., Cooper W.O., Sox C.M., et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011, 306(24):2673-2683.
123. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007, 46(7):894-921.
124. Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 2006, 7(2):61-63.
125. Dura-Trave T., Yoldi-Petri M.E., Gallinas-Victoriano F., et al. Effects of osmotic-release methylphenidate on height and weight in children with Attention-Deficit Hyperactivity Disorder (ADHD) following up to four years of treatment. J Child Neurol 2012, 27(5):604-609.
126. Poulton A., Cowell C.T. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health 2003, 39(3):180-185.
127. Spencer T.J., Faraone S.V., Biederman J., et al. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD?. J Am Acad Child Adolesc Psychiatry 2006, 45(5):527-537.
128. Swanson J., Arnold L.E., Kraemer H., et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. J Atten Disord 2008, 12(1):4-14.
129. Swanson J., Greenhill L., Wigal T., et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 2006, 45(11):1304-1313.
130. Swanson J.M., Elliott G.R., Greenhill L.L., et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007, 46(8):1015-1027.
131. Swanson J.M., Hinshaw S.P., Arnold L.E., et al. Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry 2007, 46(8):1003-1014.
132. Faraone S.V., Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010, 19(4):353-364.
133. Goldman R.D. ADHD stimulants and their effect on height in children. Can Fam Physician 2010, 56(2):145-146.
134. Spencer T.J., Kratochvil C.J., Sangal R.B., et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol 2007, 17(5):689-700.
135. Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am 2008, 17(2):459-474. xi.
136. Swanson J., Arnold L.E., Kraemer H., et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. J Atten Disord 2008, 12(1):15-43.